Cargando…

Profile of pazopanib and its potential in the treatment of epithelial ovarian cancer

Epithelial ovarian cancer (EOC) is the most lethal gynecological cancer. Recently, clinical trials have focused on novel antiangiogenic agents in combination with chemotherapy or alone in women with primary and recurrent ovarian cancer. Antiangiogenic agents include monoclonal antibodies, tyrosine-k...

Descripción completa

Detalles Bibliográficos
Autores principales:	Davidson, Brittany A, Secord, Angeles Alvarez
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Dove Medical Press 2014
Materias:	Review
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3958497/ https://www.ncbi.nlm.nih.gov/pubmed/24648773 http://dx.doi.org/10.2147/IJWH.S49781

Ejemplares similares

Quinary debulking for epithelial ovarian cancer
por: Edwards, James M., et al.
Publicado: (2012)

The role of immune checkpoint inhibition in the treatment of ovarian cancer
por: Gaillard, Stéphanie L., et al.
Publicado: (2016)

Pazopanib and Oral Cyclophosphamide in Women With Platinum-Resistant or -Refractory Epithelial Ovarian Cancer
por: Gulia, Seema, et al.
Publicado: (2020)

Targeted treatment for advanced soft tissue sarcoma: profile of pazopanib
por: Rajendra, Rajeev, et al.
Publicado: (2013)

Durable response to hormonal therapy in a patient with rapidly progressive low-grade serous ovarian cancer: A case report
por: Watson, Catherine H., et al.
Publicado: (2020)

Pazopanib for the treatment of soft-tissue sarcoma
por: Heudel, Pierre, et al.
Publicado: (2012)

Pazopanib and anti-VEGF therapy
por: Drabkin, Harry A
Publicado: (2010)

Profile of trebananib (AMG386) and its potential in the treatment of ovarian cancer
por: Liontos, Michalis, et al.
Publicado: (2014)

Relative Dose Intensity of Induction-Phase Pazopanib Treatment of Soft Tissue Sarcoma: Its Relationship with Prognoses of Pazopanib Responders
por: Nakano, Kenji, et al.
Publicado: (2019)

Pazopanib for the Treatment of Patients with Advanced Renal Cell Carcinoma
por: Lang, Joshua M., et al.
Publicado: (2010)

Factors involved in treatment preference in patients with renal cancer: pazopanib versus sunitinib
por: Mitchell, Catherine C, et al.
Publicado: (2014)

Potential Application of Curcumin and Its Analogues in the Treatment Strategy of Patients with Primary Epithelial Ovarian Cancer
por: Terlikowska, Katarzyna M., et al.
Publicado: (2014)

Profile of erlotinib and its potential in the treatment of advanced ovarian carcinoma
por: Hirte, Hal W
Publicado: (2013)

Effects of Pazopanib Monotherapy vs. Pazopanib and Topotecan Combination on Anaplastic Thyroid Cancer Cells
por: Di Desidero, Teresa, et al.
Publicado: (2019)

Analysis of in vitro chemoresponse assays in endometrioid endometrial adenocarcinoma: an observational ancillary analysis
por: Davidson, Brittany A., et al.
Publicado: (2016)

Rationale for targeted therapies and potential role of pazopanib in advanced renal cell carcinoma
por: Clark, Peter E
Publicado: (2010)

Pazopanib as a second line treatment for uterine and ovarian carcinosarcoma: a single institutional study
por: Nishikawa, Tadaaki, et al.
Publicado: (2017)

Pazopanib: Approval for Soft-Tissue Sarcoma
por: Nguyen, Diana T., et al.
Publicado: (2013)

Pazopanib in advanced soft tissue sarcomas
por: Lee, Alex T. J., et al.
Publicado: (2019)

New advancements and developments in treatment of renal cell carcinoma: focus on pazopanib
por: Cowey, C Lance, et al.
Publicado: (2010)

Pazopanib in the management of advanced soft tissue sarcomas
por: Cranmer, Lee D, et al.
Publicado: (2016)

Differential Angiogenic Gene Expression in TP53 Wild-Type and Mutant Ovarian Cancer Cell Lines
por: Davidson, Brittany Anne, et al.
Publicado: (2014)

Tumor grade and chemotherapy response in endometrioid endometrial cancer
por: Davidson, Brittany A., et al.
Publicado: (2016)

Treatment of recurrent epithelial ovarian cancer
por: Pisano, Carmela, et al.
Publicado: (2009)

Predictive Markers of First Line Pazopanib Treatment in Kidney Cancer
por: Küronya, Zsófia, et al.
Publicado: (2020)

Therapeutic and immunomodulatory potential of pazopanib in malignant phyllodes tumor
por: Ng, Dave Yong Xiang, et al.
Publicado: (2022)

Adenocarcinoma of Mullerian origin: review of pathogenesis, molecular biology, and emerging treatment paradigms
por: Cobb, Lauren Patterson, et al.
Publicado: (2015)

Interstitial Lung Disease Induced by Pazopanib Treatment
por: Ide, Shotaro, et al.
Publicado: (2017)

Pazopanib in the Treatment of Bone Sarcomas: Clinical Experience()
por: Aggerholm-Pedersen, Ninna, et al.
Publicado: (2019)

Preferences of women with epithelial ovarian cancer for aspects of genetic testing
por: Davidson, Brittany A., et al.
Publicado: (2019)

Critical appraisal of pazopanib as treatment for patients with advanced metastatic renal cell carcinoma
por: Bukowski, Ronald M
Publicado: (2011)

Tyrosine Kinase Inhibitors in the Treatment of Advanced Renal Cell Carcinoma: Focus on Pazopanib
por: Vasudev, Naveen S., et al.
Publicado: (2011)

The Landscape and Therapeutic Implications of Molecular Profiles in Epithelial Ovarian Cancer
por: Dion, Ludivine, et al.
Publicado: (2020)

The detection, treatment, and biology of epithelial ovarian cancer
por: Gubbels, Jennifer AA, et al.
Publicado: (2010)

Pazopanib, a promising option for the treatment of aggressive fibromatosis
por: Szucs, Zoltan, et al.
Publicado: (2017)

The Potential of Novel Lipid Agents for the Treatment of Chemotherapy-Resistant Human Epithelial Ovarian Cancer
por: Nachtigal, Mark W., et al.
Publicado: (2022)

Pazopanib and Statin-Induced Rhabdomyolysis
por: Logue, Jennifer M., et al.
Publicado: (2017)

Phototoxic Reaction Induced by Pazopanib
por: Udompanich, Siriorn, et al.
Publicado: (2018)

Tension Pneumothorax: Is it Sarcoma or Pazopanib?
por: Sebanayagam, Vinoja, et al.
Publicado: (2020)

Successful use of pazopanib for treatment of refractory metastatic hemangiopericytoma
por: Lee, Su Jin, et al.
Publicado: (2014)

Cannot write session to /tmp/vufind_sessions/sess_fbfjovf3afhunrb4bu3to1f95i